Arcturus Therapeutics Holdings Inc.ARCTEarnings & Financial Report

Nasdaq · pharmaceutical industry

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

NextMar 31, 2026

Revenue

$17.2M

Gross Profit

N/A

Operating Profit

$-16.5M

Net Profit

$-13.4M

Gross Margin

N/A

Operating Margin

-96.3%

Net Margin

-78.4%

YoY Growth

-58.8%

EPS

$-0.49

Financial Flow

Arcturus Therapeutics Holdings Inc. Q3 2025 Financial Summary

Arcturus Therapeutics Holdings Inc. reported revenue of $17.2M for Q3 2025, with a net profit of $-13.4M (-78.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$17.2M
Net Profit	$-13.4M
Gross Margin	N/A
Operating Margin	-96.3%
Report Period	Q3 2025

Arcturus Therapeutics Holdings Inc. Annual Revenue by Year

Arcturus Therapeutics Holdings Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $152.3M).

Year	Annual Revenue
2024	$152.3M
2023	$166.8M
2022	$206.0M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$30.9M	$38.0M	$49.9M	$41.7M	$22.8M	$29.4M	$28.3M	$17.2M
YoY Growth	-80.8%	-52.7%	374.0%	-7.7%	-26.2%	-22.7%	-43.2%	-58.8%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$429.4M	$418.8M	$388.6M	$370.7M	$344.1M	$331.8M	$309.3M	$282.3M
Liabilities	$150.9M	$154.9M	$130.0M	$108.8M	$103.1M	$98.0M	$78.2M	$57.8M
Equity	$278.5M	$264.0M	$258.6M	$261.9M	$241.0M	$233.8M	$231.1M	$224.6M